📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-10-14 16:35
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
143 announcements match the current filters (relevance ≥ 5).
ICRA Assigns [ICRA]AA+ (Stable) to Jubilant Pharmova's Proposed ₹1,400 Cr NCDs
Jubilant Pharmova has received a credit rating of [ICRA]AA+ (Stable) from ICRA Limited for its proposed Non-Convertible Debentures (NCDs) amounting to ₹1,400 crore. The proposed borrowing is substantial, representing approximately 60.5% of the company's net worth of ₹2,312 crore and about 16.3% of TTM revenue (₹8,607 crore). Currently maintaining low debt of ₹53 crore, this debt issuance indicates plans for upcoming capital deployment, potentially funding ongoing expansions such as the Montreal facility. The high-grade rating signals strong creditworthiness and allows access to debt at competitive interest rates.
Confidence: HIGH
What changedICRA has assigned a new high-investment-grade rating of [ICRA]AA+ (Stable) for proposed NCDs of ₹1,400 crore.
Why it mattersSecuring an AA+ rating confirms balance sheet strength and facilitates lower cost of borrowing as the company potentially expands its leverage for strategic growth projects.
Proposed NCD Amount: 1,400.00 croreRating Assigned: [ICRA]AA+ (Stable)Proposed NCDs vs Net Worth: ~60.5%Proposed NCDs vs TTM Revenue: ~16.3%
📅 Short termNeutral to mildly positive as the rating assignment prepares the company for a large debt issue on favorable credit terms.
📈 Long termIf issued fully, this will significantly increase leverage from the current ₹53 crore base, making long-term return on capital dependent on the returns generated by the deployed funds.
⚠ Risk flags
- Substantial increase in leverage if the entire ₹1,400 crore is drawn down against current debt of ₹53 crore
- Terms, coupon rates, and specific end-use not detailed in the rating letter
Key Highlights
ICRA assigned [ICRA]AA+ (Stable) rating to proposed Non-Convertible Debentures of ₹1,400.00 crore
Rating communication received from ICRA on October 13, 2026
Proposed debt represents ~60.5% of net worth (₹2,312 cr) against current debt of ₹53 cr
Company retains an investment-grade rating enabling cost-effective debt capital access
👀 What to Watch
Track subsequent board approvals or filings detailing coupon rates, tenure, and exact utilization of the ₹1,400 crore proceeds (e.g., capex vs. refinancing).
Jubilant Pharmova Approves ₹800 Cr NCD Issuance, Seeks Postal Ballot for Up to ₹2,500 Cr
Jubilant Pharmova's Board of Directors has approved the issuance of listed, rated, redeemable Non-Convertible Debentures (NCDs) aggregating up to ₹800 crore on a private placement basis. The company is also seeking shareholder approval via postal ballot to issue debt securities up to an aggregate limit of ₹2,500 crore over a one-year period. The ₹800 crore issuance has a tenure of up to five years and will be listed on the BSE. Relative to the company's financial profile, the ₹800 crore issuance represents approximately 34.6% of net worth (₹2,312 crore) and 9.3% of TTM revenue (₹8,607 crore).
Confidence: HIGH
What changedThe Board approved a specific ₹800 crore NCD issuance and initiated shareholder approval for an overall ₹2,500 crore debt borrowing headroom.
Why it mattersIncreases leverage headroom substantially from the current low debt level of ₹53 crore, likely providing liquidity for ongoing capital projects such as sterile injectables capacity expansions.
Approved NCD Issue Size: ₹800 crorePostal Ballot Debt Limit: ₹2,500 croreFace Value per NCD: ₹1,00,000Issue Size vs Net Worth: ~34.6%Issue Size vs TTM Revenue: ~9.3%
📅 Short termMarket reaction is expected to be neutral pending disclosure of the exact coupon rate discovered through bidding and end-use details.
📈 Long termHigher debt will increase leverage from current negligible levels (D/E: 0.02), but supports funding for ongoing international capacity expansion programs.
⚠ Risk flags
- Increased leverage and future interest expense burden
- Coupon rate is yet to be discovered via bidding
Key Highlights
Approved issuance of up to 80,000 NCDs of face value ₹1,00,000 each, totaling up to ₹800 crore
Seeking shareholder approval via postal ballot for debt issuance up to ₹2,500 crore over one year
Instrument tenure is up to five years from the deemed date of allotment
Securities will be listed on BSE, with coupon/interest to be discovered via bidding
👀 What to Watch
Track the upcoming postal ballot voting results and the final pricing/coupon rate determined during the bidding process to assess borrowing costs.
Jubilant Pharmova Approves ₹800 Cr NCD Issuance, Seeks Postal Ballot for Up to ₹2,500 Cr
Jubilant Pharmova's Board of Directors has approved the issuance of listed, rated, redeemable Non-Convertible Debentures (NCDs) aggregating up to ₹800 crore on a private placement basis. The company is also seeking shareholder approval via postal ballot to issue debt securities up to an aggregate limit of ₹2,500 crore over a one-year period. The ₹800 crore issuance has a tenure of up to five years and will be listed on the BSE. Relative to the company's financial profile, the ₹800 crore issuance represents approximately 34.6% of net worth (₹2,312 crore) and 9.3% of TTM revenue (₹8,607 crore).
Confidence: HIGH
What changedThe Board approved a specific ₹800 crore NCD issuance and initiated shareholder approval for an overall ₹2,500 crore debt borrowing headroom.
Why it mattersIncreases leverage headroom substantially from the current low debt level of ₹53 crore, likely providing liquidity for ongoing capital projects such as sterile injectables capacity expansions.
Approved NCD Issue Size: ₹800 crorePostal Ballot Debt Limit: ₹2,500 croreFace Value per NCD: ₹1,00,000Issue Size vs Net Worth: ~34.6%Issue Size vs TTM Revenue: ~9.3%
📅 Short termMarket reaction is expected to be neutral pending disclosure of the exact coupon rate discovered through bidding and end-use details.
📈 Long termHigher debt will increase leverage from current negligible levels (D/E: 0.02), but supports funding for ongoing international capacity expansion programs.
⚠ Risk flags
- Increased leverage and future interest expense burden
- Coupon rate is yet to be discovered via bidding
Key Highlights
Approved issuance of up to 80,000 NCDs of face value ₹1,00,000 each, totaling up to ₹800 crore
Seeking shareholder approval via postal ballot for debt issuance up to ₹2,500 crore over one year
Instrument tenure is up to five years from the deemed date of allotment
Securities will be listed on BSE, with coupon/interest to be discovered via bidding
👀 What to Watch
Track the upcoming postal ballot voting results and the final pricing/coupon rate determined during the bidding process to assess borrowing costs.
JUBLCPL Advances Demerger Scheme; NCLT Sets Next Hearing for Dec 3, 2026
Jubilant Agri and Consumer Products Limited (JUBLCPL) announced progress on its proposed demerger scheme into Jubilant Agri Solutions Limited (JASL). The Hon'ble NCLT Allahabad Bench, via an order dated October 08, 2026, directed the issuance of notices to statutory and regulatory authorities under Section 230(5) of the Companies Act, 2013. The NCLT has scheduled the next hearing for December 03, 2026, to review representations or objections.
Confidence: HIGH
What changedNCLT Allahabad has accepted the second motion petition for hearing and directed regulatory notifications.
Why it mattersThe demerger aims to separate the agri-business from the higher-margin Performance Polymers and Adhesives business, unlocking distinct business focus and valuation.
NCLT Order Date: October 08, 2026Next Hearing Date: December 03, 2026Market Capitalization: Rs 2890 Cr
📅 Short termProcedural step in the NCLT approval process; minimal near-term share price reaction expected until final clearance.
📈 Long termCompleting the demerger will structurally isolate the cyclical agri-inputs division from the core consumer adhesive and polymer operations.
⚠ Risk flags
- Potential delays in regulatory representations or court approvals
- Execution timeline risks typical of corporate restructurings
Key Highlights
NCLT Allahabad Bench issued order on October 08, 2026, regarding the second motion petition for demerger.
Order directs notices under Section 230(5) of the Companies Act, 2013 to relevant statutory authorities.
Next NCLT hearing in the demerger matter scheduled for December 03, 2026.
👀 What to Watch
Track the upcoming NCLT hearing on December 03, 2026, and watch for any objections or observations raised by regulatory authorities regarding the demerger scheme.
CAD 94.5M Capex: Jubilant Pharmova to Double RUBY-FILL® Capacity with CAD 23.8M Canadian Govt Support
Jubilant Pharmova's subsidiary, Jubilant Draximage Inc., announced a capital expenditure of CAD 94.5 million to modernize and expand its Kirkland, Québec facility. The expansion is aimed at doubling the production capacity of its flagship radiopharmaceutical product, RUBY-FILL®, driven by customer demand doubling over the last 3 years. The project is backed by CAD 23.8 million in financial support from the Government of Canada through its Strategic Response Fund. With Jubilant's net worth at Rs 2,312 Cr, the ~CAD 94.5M investment (approx. Rs 570-600 Cr) represents a meaningful ~25% commitment relative to net worth.
Confidence: HIGH
What changedJubilant Pharmova committed CAD 94.5 million to double capacity for RUBY-FILL® in Canada, securing CAD 23.8 million in government funding.
Why it mattersRadiopharma is a high-barrier, high-margin growth driver for the company, and doubling capacity addresses elevated global demand for PET imaging tools while de-risking capital via government subsidies.
Total investment: CAD 94.5 millionGovernment financial support: CAD 23.8 millionCustomer base growth (last 3 yrs): doubledUS Radiopharmacies network size: 45 pharmacies
📅 Short termPositive sentiment driver as Canadian government co-funding cushions capex intensity, though near-term P&L impact will remain muted until construction progresses.
📈 Long termEnhances scale in the proprietary Radiopharma CDMO/specialty segment, reinforcing Jubilant's shift away from low-margin generics toward differentiated nuclear medicine.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Project execution and regulatory validation timelines for nuclear facility expansion
- Concentration on specific product uptake (RUBY-FILL®)
Key Highlights
Investment of CAD 94.5 million to modernize and expand Kirkland, Québec facility
CAD 23.8 million financial support provided by the Government of Canada
Aims to double manufacturing capacity of flagship cardiac PET imaging product RUBY-FILL®
Customer base for RUBY-FILL® has doubled in the last 3 years
👀 What to Watch
Track management commentary on project commissioning milestones and expected commercial launch dates for the expanded capacity in upcoming quarterly earnings calls.
JUBLFOOD Q2FY27 Update: Revenue Up 11.9% to ₹2,608.7 Cr; Added 108 Net Stores
Jubilant FoodWorks reported provisional Q2FY27 consolidated revenue of Rs. 26,087 million (Rs. 2,608.7 cr), marking an 11.9% YoY increase. Standalone revenue grew 11.6% YoY to Rs. 18,858 million (Rs. 1,885.8 cr). Domino's India delivered a Like-for-Like (LFL) growth of 4.1%, while Domino's Eurasia saw an LFL contraction of 2.1% (post Ind AS 29 hyperinflation adjustments). The group expanded its footprint by adding net 108 stores during the quarter, bringing the total store count across 4 brands and 6 markets to 3,820.
Confidence: HIGH
What changedJFL reported provisional revenue growth of 11.9% YoY for Q2FY27 and expanded its network across brands to 3,820 stores, alongside reclassifying Dunkin' as a discontinued operation.
Why it mattersTopline growth remains steady around 11-12%, driven predominantly by network expansion (88 stores in India), although LFL growth for Domino's India slowed to 4.1% and Eurasia contracted 2.1%.
Consolidated Revenue (Q2FY27): Rs. 26,087 millionConsolidated Revenue YoY Growth: 11.9%Domino's India LFL Growth: 4.1%Net Group Store Additions: 108Total Store Count: 3,820
📅 Short termMarket sentiment may be balanced; healthy consolidated store addition and double-digit revenue growth are offset by moderation in Indian LFL growth (4.1%) and a negative LFL in Eurasia.
📈 Long termNetwork expansion continues steadily toward scaling Domino's and emerging brands, though sustaining LFL ticket and volume growth will be vital for medium-term margin expansion.
⚠ Risk flags
- Subdued LFL growth in Domino's India at 4.1%
- Hyperinflation and macroeconomic volatility in Turkey/Eurasia leading to -2.1% LFL
- Discontinuation of Dunkin' brand business operations
Key Highlights
Consolidated revenue from operations rose 11.9% YoY to Rs. 26,087 million
Standalone revenue from operations reached Rs. 18,858 million, up 11.6% YoY
Domino's India recorded LFL growth of 4.1%, while Domino's Eurasia declined 2.1%
Group network expanded by net 108 stores to 3,820 stores, including 88 new Domino's India stores
👀 What to Watch
Track the full quarterly results for detailed EBITDA margins, operating profit, and updates on the impact of reclassifying Dunkin' as a discontinued operation.
UBL receives ₹100.83 crore aggregate income tax refund for AY14 and AY21
United Breweries Limited has received an aggregate income tax refund of ₹100.83 crores pursuant to orders giving effect to ITAT directions. This includes a ₹82.73 crore refund for AY 2013-14 (containing ₹25.65 crore interest) received on October 05, 2026, and ₹18.10 crore for AY 2020-21 (containing ₹4.79 crore interest) received on October 03, 2026. The total refund equals approximately 25.5% of TTM PAT (₹395 crore), offering a direct boost to liquidity and other income through the ₹30.44 crore total interest component.
Confidence: HIGH
What changedUBL received ₹100.83 crores in cash tax refunds following assessment orders giving effect to ITAT decisions.
Why it mattersThe cash inflow improves working capital and represents ~25.5% of TTM PAT, with ₹30.44 crores hitting P&L as interest income.
Total refund received: ₹100.83 croresAY 2013-14 refund (incl. interest): ₹82.73 croresAY 2020-21 refund (incl. interest): ₹18.10 croresTotal interest component: ₹30.44 croresRefund vs TTM PAT: ~25.5%
📅 Short termPositive for cash flows and near-term reported profitability due to the one-off interest income recognition.
📈 Long termLimited; this is a one-off tax litigation resolution and does not alter core operational brewing fundamentals.
⚠ Risk flags
- Remaining disallowed matters remain pending before the Hon'ble High Court of Karnataka and appellate authorities
Key Highlights
Received aggregate tax refund of ₹100.83 crores across AY 2013-14 and AY 2020-21
AY 2013-14 refund stands at ₹82.73 crores, including interest of ₹25.65 crores
AY 2020-21 refund stands at ₹18.10 crores, including interest of ₹4.79 crores
Remaining contested issues continue to be litigated before the Karnataka High Court and appellate authorities
👀 What to Watch
Track the recognition of ₹30.44 crores interest income in upcoming quarterly earnings and monitor the status of unresolved issues pending before the Karnataka High Court.
Jubilant Ingrevia to Incorporate WOS with ₹10 Cr Capital for 40% Stake in Zettaone
Jubilant Ingrevia's Board approved the incorporation of a wholly owned subsidiary (WOS), Jubilant Advanced Electronics Limited, with an initial subscription capital of up to ₹10 crore. This new entity will serve as the vehicle to execute the previously announced acquisition of a 40% strategic stake in Zettaone Technologies India Private Limited. The restructuring is aimed at building an integrated presence across electronics manufacturing services (EDMS) and semiconductor chemicals under the company's 'Pinnacle' growth strategy. Relative to Jubilant Ingrevia's TTM revenue of ₹4,651 crore and net worth of ₹2,640 crore, the initial ₹10 crore equity commitment is minor (<0.4% of net worth).
Confidence: HIGH
What changedThe planned 40% strategic stake purchase in Zettaone will now be held via a newly formed wholly owned subsidiary rather than directly by Jubilant Ingrevia.
Why it mattersCreates a distinct corporate entity to house semiconductor and electronics manufacturing operations, separating it from the core specialty chemical intermediates business.
WOS Initial Subscription Capital: Up to Rs.10,00,00,000/-Initial Capital vs Net Worth: ~0.38%Stake in Zettaone: 40%Share Face Value: Rs 10/- each
📅 Short termNeutral trading impact as the ₹10 crore initial capital commitment is small and represents an operational restructuring of a previously disclosed deal.
📈 Long termProvides strategic separation and operational flexibility to scale its high-margin electronics and semiconductor solutions alongside the Pinnacle growth roadmap.
⚠ Risk flags
- Execution and integration risks in the unfamiliar EDMS sector
- Final transaction consideration for the 40% Zettaone stake remains undisclosed
Key Highlights
Approved incorporation of wholly owned subsidiary Jubilant Advanced Electronics Limited
Initial cash subscription of up to ₹10,00,00,000 (up to 1,00,00,000 equity shares at ₹10 face value)
Proposed acquisition of 40% strategic equity stake in Zettaone Technologies will now route through the WOS
Targeted industry focus is Electronic Products, EDMS, and Semi-Conductor materials
👀 What to Watch
Track the completion timeline for the incorporation and subsequent formal closing of the 40% equity acquisition in Zettaone Technologies, alongside capital allocation details.
Jubilant Ingrevia to Incorporate WOS with ₹10 Cr Capital for 40% Stake in Zettaone
Jubilant Ingrevia's Board approved the incorporation of a wholly owned subsidiary (WOS), Jubilant Advanced Electronics Limited, with an initial subscription capital of up to ₹10 crore. This new entity will serve as the vehicle to execute the previously announced acquisition of a 40% strategic stake in Zettaone Technologies India Private Limited. The restructuring is aimed at building an integrated presence across electronics manufacturing services (EDMS) and semiconductor chemicals under the company's 'Pinnacle' growth strategy. Relative to Jubilant Ingrevia's TTM revenue of ₹4,651 crore and net worth of ₹2,640 crore, the initial ₹10 crore equity commitment is minor (<0.4% of net worth).
Confidence: HIGH
What changedThe planned 40% strategic stake purchase in Zettaone will now be held via a newly formed wholly owned subsidiary rather than directly by Jubilant Ingrevia.
Why it mattersCreates a distinct corporate entity to house semiconductor and electronics manufacturing operations, separating it from the core specialty chemical intermediates business.
WOS Initial Subscription Capital: Up to Rs.10,00,00,000/-Initial Capital vs Net Worth: ~0.38%Stake in Zettaone: 40%Share Face Value: Rs 10/- each
📅 Short termNeutral trading impact as the ₹10 crore initial capital commitment is small and represents an operational restructuring of a previously disclosed deal.
📈 Long termProvides strategic separation and operational flexibility to scale its high-margin electronics and semiconductor solutions alongside the Pinnacle growth roadmap.
⚠ Risk flags
- Execution and integration risks in the unfamiliar EDMS sector
- Final transaction consideration for the 40% Zettaone stake remains undisclosed
Key Highlights
Approved incorporation of wholly owned subsidiary Jubilant Advanced Electronics Limited
Initial cash subscription of up to ₹10,00,00,000 (up to 1,00,00,000 equity shares at ₹10 face value)
Proposed acquisition of 40% strategic equity stake in Zettaone Technologies will now route through the WOS
Targeted industry focus is Electronic Products, EDMS, and Semi-Conductor materials
👀 What to Watch
Track the completion timeline for the incorporation and subsequent formal closing of the 40% equity acquisition in Zettaone Technologies, alongside capital allocation details.
UBL Faces ₹54.83 Cr Penalty Demand from Income Tax Department Across Seven Assessment Years
United Breweries Limited has received penalty orders from the Income Tax Department's National Faceless Assessment Centre (NFAC) totaling ₹54.83 crore across multiple assessment years (AY 2013-14 to AY 2022-23). The single largest penalty demand is ₹26.99 crore for AY 2022-23 under section 270A. The company noted that the underlying assessment orders are already under appeal before the ITAT or CIT(A), and that NFAC levied penalties prematurely including computational errors. Relative to UBL's TTM PAT of ₹395 crore, the total disputed penalty represents approximately 13.9%, though management does not anticipate a material financial impact beyond minimal statutory pre-deposits.
Confidence: HIGH
What changedUBL received penalty orders from the Income Tax NFAC totaling ₹54.83 crore across seven assessment orders on September 28 and 29, 2026.
Why it mattersWhile the total demand represents ~13.9% of TTM PAT (₹395 crore), the company is contesting the orders since underlying quantum disputes remain sub judice.
Total penalty demand: ₹54,82,99,656Penalty vs TTM PAT: ~13.9%Largest AY demand (AY 2022-23): ₹26,98,91,806Orders received dates: September 28, 2026, and September 29, 2026
📅 Short termLimited operational disruption expected; near-term focus will be on legal appeals and potential minor cash outflows towards statutory pre-deposits.
📈 Long termLimited; tax penalty litigation is commonplace and UBL has grounds contesting the parallel penalty proceedings while quantum appeals are sub judice.
⚠ Risk flags
- Potential cash lock-up due to mandatory statutory pre-deposits for filing appeals
- Adverse ITAT or High Court rulings could formalize tax liabilities
Key Highlights
Aggregate penalty demand of ₹54,82,99,656 across AY 2013-14, 2014-15, 2017-18, 2018-19, 2020-21, and 2022-23
Largest single penalty demand is ₹26,98,91,806 levied under section 270A for AY 2022-23
Penalties levied under Section 271(1)(c) and Section 270A while underlying quantum appeals remain pending before ITAT and CIT(A)
Alleged clerical errors by NFAC include an excess penalty of ₹7.55 crore for AY 2022-23 and a duplicative penalty of ₹99.36 lakh
👀 What to Watch
Track the admission of appeals before the ITAT/CIT(A) and whether any statutory pre-deposit requirements cause cash outflows in upcoming quarters.
CARE Reaffirms Jubilant Agri's ₹625 Cr Bank Facilities at 'CARE A+; Stable / CARE A1+'
CARE Ratings Limited has reaffirmed Jubilant Agri and Consumer Products Limited's credit ratings for its bank facilities totalling ₹625.00 crore. The Long Term/Short Term Bank Facilities stand reaffirmed at 'CARE A+; Stable / CARE A1+'. Additionally, a separate Long Term Bank Facility rating was withdrawn. The rated debt size of ₹625.00 crore represents approximately 65.3% of the company's TTM revenue of ₹957 crore.
Confidence: HIGH
What changedCARE Ratings reaffirmed the existing 'CARE A+; Stable / CARE A1+' credit rating on ₹625 crore of bank facilities and withdrew a separate long-term facility.
Why it mattersMaintains stability in borrowing costs and lender access for Jubilant Agri's ongoing operational and capex funding needs.
Total rated bank facilities: Rs. 625.00 CroreRated facility vs TTM revenue: ~65.3%Long-term credit rating: CARE A+; StableShort-term credit rating: CARE A1+
📅 Short termNeutral impact expected on stock price as ratings are reaffirmed with no change in outlook or borrowing costs.
📈 Long termLimited; reflects stable credit profile supporting the company's business model and planned capacity expansions.
⚠ Risk flags
- Exposure to volatile input costs such as Vinyl Acetate Monomer (VAM) and Rock Phosphate
Key Highlights
CARE Ratings reaffirmed ratings on bank facilities amounting to ₹625.00 crore
Long Term / Short Term rating maintained at 'CARE A+; Stable / CARE A1+'
Previous separate Long Term Bank Facilities rating has been withdrawn
Rated debt of ₹625.00 crore equals ~65.3% of TTM revenue of ₹957 crore
👀 What to Watch
Track the company's upcoming quarterly financial results and working capital utilization to gauge leverage levels against the reaffirmed facilities.
USFDA Classifies Spokane CMO Facility Inspection as 'Voluntary Action Indicated' (VAI)
Jubilant Pharmova announced that the USFDA has concluded its review of the Establishment Inspection Report (EIR) for the Jubilant HollisterStier LLC CMO facility located in Spokane, Washington, USA. The inspection was carried out from June 8, 2026, to June 17, 2026, and the regulator has determined a 'Voluntary Action Indicated' (VAI) classification. A VAI status indicates objectionable conditions were found but no administrative or regulatory sanctions are recommended, clearing immediate regulatory overhang for the site.
Confidence: HIGH
What changedUSFDA concluded its review of the Spokane CMO facility and classified it as VAI, lifting regulatory uncertainty.
Why it mattersThe Spokane facility is a critical CDMO site housing sterile injectable capacity; a VAI classification avoids regulatory escalation (like Warning Letters or Import Alerts) and clears the path for seamless commercial supply.
Inspection start date: June 8, 2026Inspection end date: June 17, 2026Receipt date (IST): September 10, 2026, 11:22 PM (IST)
📅 Short termPositive sentiment relief as the closure of the EIR with a VAI classification removes near-term compliance headwinds.
📈 Long termSupports commercial scale-up of the sterile injectables CMO business, including the newly operational third line at Spokane, without regulatory disruption.
⚠ Risk flags
- Voluntary corrective actions must still be maintained and satisfactorily addressed before future audits.
Key Highlights
Inspection conducted by USFDA from June 8, 2026, to June 17, 2026.
USFDA determined the classification as 'Voluntary Action Indicated (VAI)'.
Communication received by the company on September 10, 2026, at 10:52 AM PST.
Facility belongs to subsidiary Jubilant HollisterStier LLC, which operates key sterile injectables CMO capacity.
👀 What to Watch
Track the ramp-up of the operational third line at Spokane and monitor subsequent quarterly updates on sterile injectables CDMO revenue contribution.
JUBLCPL: 100% Unsecured Creditors Approve Agri Business Demerger into Jubilant Agri Solutions
Unsecured creditors of Jubilant Agri and Consumer Products Limited (JUBLCPL) have unanimously approved the proposed Scheme of Arrangement for the demerger of its Agri Business into Jubilant Agri Solutions Limited. In the NCLT-convened meeting held on September 05, 2026, all 24 unsecured creditors present, representing a debt value of Rs 12.59 crore, voted 100% in favour of the resolution. The meeting was conducted via poll pursuant to an NCLT Allahabad Bench order dated July 08, 2026. This approval achieves a critical statutory milestone in separating the agricultural inputs vertical from the performance polymers and consumer business.
Confidence: HIGH
What changedUnsecured creditors have officially given unanimous approval to the demerger of JUBLCPL's Agri Business undertaking into Jubilant Agri Solutions Limited.
Why it mattersClears a mandatory regulatory hurdle under Sections 230-232 of the Companies Act, moving JUBLCPL closer to unlocking value and focusing on high-margin Performance Polymers & Adhesives.
Debt value voted in favour: Rs 12,59,00,064Unsecured creditors voted in favour: 24 (100%)Meeting date: 05-09-2026
📅 Short termClear procedural progress removes restructuring bottlenecks and provides visibility on scheme timelines.
📈 Long termPost-demerger, JUBLCPL aims to emerge as a pure-play specialty polymer and adhesive player, while the agri entity independently focuses on bulk fertilizers and nutrients.
⚠ Risk flags
- Pending final approval and sanction of the Scheme of Arrangement by the Hon'ble NCLT Allahabad Bench
Key Highlights
100% of votes cast in value and number were in favour of the demerger resolution.
24 unsecured creditors holding debt worth Rs 12.59 crore participated and voted in the meeting.
The meeting was convened following the Hon'ble NCLT Allahabad Bench order dated July 08, 2026.
Largest voting creditors included Jubilant Ingrevia Ltd (Rs 6.16 cr) and Macro Polymer (Rs 1.28 cr).
👀 What to Watch
Track upcoming NCLT court hearings for final scheme sanction, effective date announcement, and subsequent entitlement/record date details for Jubilant Agri Solutions Limited.
JUBLCPL Shareholders Approve Agri Business Demerger with 99.99% Majority
Jubilant Agri and Consumer Products Limited (JUBLCPL) announced that its equity shareholders have approved the Scheme of Arrangement for the demerger of its Agri Business into Jubilant Agri Solutions Limited at the NCLT-convened meeting held on September 05, 2026. The special resolution was passed overwhelmingly with 99.99% of polled votes in favour (1,16,36,273 votes) and only 597 votes against. Out of 1,51,52,493 total outstanding shares, 1,16,36,870 shares were polled, representing a 76.80% voter turnout. The demerger aims to separate the farm-input business to allow dedicated focus on higher-margin Performance Polymers and Adhesives.
Confidence: HIGH
What changedEquity shareholders have formally voted and approved the Scheme of Arrangement to demerge the Agri Business into Jubilant Agri Solutions Limited.
Why it mattersThis formal shareholder nod clears a critical statutory hurdle, paving the way to segregate the cyclical fertilizer business from high-margin polymer and adhesive operations.
Votes in favour (%): 99.9949%Votes polled in favour: 11,636,273Votes against: 597Voter turnout: 76.7984%Total outstanding shares: 15,152,493
📅 Short termClearance from shareholders enables the company to petition the NCLT for final approval, maintaining momentum on corporate restructuring.
📈 Long termPost-demerger, JUBLCPL will operate as a focused specialty chemicals player (Performance Polymers and Consumer Adhesives), potentially improving margin profiles and capital allocation.
⚠ Risk flags
- Pending final approval and sanction from the Hon'ble NCLT Allahabad Bench and regulatory authorities.
Key Highlights
Shareholders approved the demerger scheme with 99.9949% votes in favour (1,16,36,273 shares).
Only 597 shares (0.0051%) voted against the proposed restructuring scheme.
Overall voting turnout was 76.80% across 1,16,36,870 polled shares out of 1,51,52,493 total shares.
Meeting was convened pursuant to the Hon'ble NCLT Allahabad Bench order dated July 08, 2026.
👀 What to Watch
Track subsequent proceedings at the NCLT Allahabad Bench for the final sanction order of the scheme, followed by announcement of the record date and share entitlement ratio for the resulting entity.
JUBLCPL Concludes NCLT Creditors Meeting on Demerger into Jubilant Agri Solutions
Jubilant Agri and Consumer Products Limited (JUBLCPL) conducted its Hon'ble NCLT-convened meeting of unsecured creditors on September 05, 2026. The meeting was held to consider and vote on the proposed Scheme of Arrangement for the demerger of its agri-business into Jubilant Agri Solutions Limited. A total of 24 unsecured creditors attended the meeting in person, via proxies, or through authorized representatives. The voting results on the resolution will be declared separately upon receipt of the Scrutinizer's report.
Confidence: HIGH
What changedJUBLCPL has completed the NCLT-mandated unsecured creditors' meeting and voting process for its proposed corporate demerger.
Why it mattersThe demerger is intended to separate the agri-business into Jubilant Agri Solutions Limited, allowing JUBLCPL to focus on higher-margin performance polymers and adhesives.
Creditors in attendance: 24Meeting date: September 05, 2026NCLT Order date: July 08, 2026TTM Revenue (Context): ₹957 cr
📅 Short termNeutral procedural progress; focus will be on the scrutinizer's report confirming approval percentages.
📈 Long termSuccessful demerger will streamline operations, allowing dedicated capital allocation between the specialty polymer business and the commodity agri-nutrients business.
⚠ Risk flags
- Pending final approval from NCLT and regulatory authorities
- Potential delays in execution of the demerger process
Key Highlights
NCLT-convened meeting of unsecured creditors held on September 05, 2026, pursuant to NCLT order dated July 08, 2026
24 unsecured creditors attended the meeting in person, through authorized representatives, or via valid proxies
Meeting deliberated and conducted voting by poll on the Scheme of Arrangement for Demerger between JUBLCPL and Jubilant Agri Solutions Limited
Formal voting results to be submitted to stock exchanges following the scrutinizer's compilation
👀 What to Watch
Track the upcoming disclosure of the scrutinizer's voting results and subsequent NCLT final sanction hearings to monitor the timeline for business demerger.
JUBLCPL Concludes NCLT Shareholder Meeting on Agri-Business Demerger Scheme
Jubilant Agri and Consumer Products Limited (JUBLCPL) conducted an NCLT-convened equity shareholders meeting on September 05, 2026, to approve the Scheme of Arrangement for demerging its agri-business into Jubilant Agri Solutions Limited. A total of 47 equity shareholders attended the meeting, comprising 17 in-person or authorized representatives and 30 by proxy. Remote e-voting was held from September 02 to September 04, 2026, supplemented by a physical poll at the venue. Combined voting results and the scrutinizer report will be declared and submitted to the stock exchanges separately.
Confidence: HIGH
What changedJUBLCPL completed the shareholder voting stage mandated by the Hon'ble NCLT for the proposed demerger of its agri-business.
Why it mattersThe demerger is a key corporate restructuring milestone aimed at separating the cyclical agri-inputs division to focus core operations on higher-margin Performance Polymers and Adhesives.
Meeting date: September 05, 2026Shareholder attendees: 47In-person attendees: 17Proxy attendees: 30Remote e-voting period: September 02 to September 04, 2026
📅 Short termScrutinizer voting results should be submitted shortly; approval will clear the way for final NCLT sanction hearings.
📈 Long termIf sanctioned by the NCLT, the separation creates distinct corporate entities for the agri-inputs and specialty performance polymers businesses.
⚠ Risk flags
- Pending final NCLT sanction and regulatory approvals
- Execution and business allocation risks upon demerger completion
Key Highlights
NCLT-convened shareholder meeting conducted on September 05, 2026, for the proposed demerger scheme.
Proposed scheme demerges the agri-business into Jubilant Agri Solutions Limited.
A total of 47 equity shareholders attended the meeting (17 in person/reps and 30 by proxy).
Remote e-voting completed across September 02–04, 2026; formal scrutinizer voting results to follow.
👀 What to Watch
Track the upcoming disclosure of final scrutinizer voting results and subsequent NCLT hearing dates for final approval of the demerger scheme.
Jubilant Pharmova Receives ₹87.31 Cr GST Show Cause Notice for FY23
Jubilant Pharmova has received a Show Cause Notice from the Assistant Commissioner of Commercial Taxes (Enforcement)-4, Mysore, proposing a total demand of ₹87.31 crore for FY 2022-23. The demand includes ₹33.58 crore in GST, ₹20.15 crore in interest, and ₹33.58 crore in penalty concerning alleged ineligible/excess ITC and E-way bill records. The proposed demand represents approximately 24.9% of the company's TTM net profit of ₹351 crore. Jubilant Pharmova stated it will file a detailed reply contesting the notice on merits and expects no financial or operational impact.
Confidence: HIGH
What changedCommercial tax authorities in Mysore issued a Show Cause Notice proposing a ₹87.31 crore tax, interest, and penalty demand for FY 2022-23.
Why it mattersWhile currently at the show cause stage, the proposed ₹87.31 crore demand is sizable relative to the company's annual net earnings (~25% of TTM PAT of ₹351 crore).
Total proposed demand: Rs. 87.31 CrGST Tax component: Rs. 33.58 CrInterest component: Rs. 20.15 CrPenalty component: Rs. 33.58 CrDemand vs TTM PAT: ~24.9%Financial year involved: 2022-2023
📅 Short termThe company will file a reply contesting the notice; no immediate cash outflow or balance sheet hit is expected until adjudication.
📈 Long termLimited, as input tax credit and E-way bill disputes are typically resolved or appealed through standard quasi-judicial tax channels.
⚠ Risk flags
- Potential liability of ₹87.31 crore if contested grounds are not accepted by tax authorities
- Protracted tax litigation
Key Highlights
Total tax demand proposed of ₹87.31 crore for FY 2022-2023.
Breakdown comprises ₹33.58 crore GST tax, ₹20.15 crore interest, and ₹33.58 crore penalty.
Allegations relate to ineligible ITC, excess ITC availed, and differential tax liability based on E-way bill records.
Notice received on August 31, 2026; company preparing a detailed reply to contest the demand.
👀 What to Watch
Monitor subsequent disclosures on whether the tax authority accepts the company's reply or issues an adverse assessment order.
UBL Invests ₹110 Cr to Commission New 40,000 Cans/Hour Line at Ellora Brewery, Maharashtra
United Breweries Limited (UBL) has announced the commissioning of a new canning line at its Ellora Brewery in Chhatrapati Sambhajinagar, Maharashtra, with an investment of ₹110 crore (~0.97% of TTM revenue). The facility features a capacity of 40,000 cans per hour, making it the brewery's first canning line and among the fastest in UBL's network. The line is expected to become operational in September 2026, subject to statutory approvals, to meet rising consumer demand for canned beer and support premiumization across brands like Kingfisher Strong and London Pilsner. This follows a similar canning expansion commissioned at UBL's Nizam Brewery in Telangana in July 2026.
Confidence: HIGH
What changedUBL added a dedicated high-speed canning line (40,000 cans/hr) to its Ellora Brewery in Maharashtra at a cost of ₹110 crore.
Why it mattersEnables UBL to capture growing consumer preference for canned beer and premium formats in Maharashtra, optimizing brewery utilization and logistics.
Investment Amount: ₹110 croreInvestment vs TTM Revenue: ~0.97%Canning Capacity: 40,000 cans per hourExisting Packaging Capacity: up to 1.5 million cases per monthExpected Commissioning: September 2026
📅 Short termPositive operational update demonstrating continuous capex rollout; minimal immediate impact on quarterly numbers until fully ramped up.
📈 Long termSupports margin expansion and product mix premiumization in a key high-consumption state (Maharashtra).
⚠ Risk flags
- Subject to statutory regulatory approvals before becoming operational
- State-level alcohol taxation and distribution regulations
Key Highlights
₹110 crore investment in Ellora Brewery's first canning line in Maharashtra
Line capacity of 40,000 cans per hour alongside existing packaging capacity of up to 1.5 million cases per month
Scheduled to become operational in September 2026, subject to statutory approvals
Follows previous canning line commissioning at Nizam Brewery, Telangana in July 2026
👀 What to Watch
Track receipt of final statutory approvals and commercial output ramp-up during Q2/Q3 FY27 to gauge volume and mix improvement in Maharashtra.
Jubilant Pharmova Unit Gets ₹105.5 Cr GST Show Cause Notice
Jubilant Pharmova's wholly-owned subsidiary, Jubilant Generics Limited, received a Show Cause Notice from the CGST Division, Roorkee on August 27, 2026. The notice proposes a GST demand of ₹52.75 crore and an equivalent penalty of ₹52.75 crore (totaling ₹105.50 crore plus unquantified interest) for FY 2020-21 and FY 2021-22. The dispute pertains to alleged simultaneous availment of IGST refund under Rule 96 and Advance Authorisation benefits. The company stated the notice is legally incorrect, plans to contest it, and expects no financial impact.
Confidence: HIGH
What changedJubilant Generics received a Show Cause Notice alleging improper IGST refund availment alongside Advance Authorisation benefits, proposing tax and penalties of ₹105.50 crore.
Why it mattersWhile at the show-cause stage, the total quantified claim of ₹105.50 crore is substantial relative to annual profitability (~30% of TTM PAT), though the company intends to contest it vigorously.
GST Tax Demand: ₹52.75 CrPenalty Proposed: ₹52.75 CrInterest Amount: Not QuantifiedTotal Quantified Demand vs TTM PAT: ~30.1%
📅 Short termSubmissions will be filed contesting the show cause notice; no immediate cash outflow is required until adjudication.
📈 Long termLimited operational disruption expected, but potential legal or appellate proceedings could extend over several quarters if the demand is confirmed.
⚠ Risk flags
- Unquantified interest liability in addition to the ₹105.50 crore demand
- Adverse adjudication could impact net earnings if provisions become necessary
Key Highlights
Subsidiary Jubilant Generics receives Show Cause Notice for FY 2020-21 and FY 2021-22.
Demands ₹52.75 crore in GST tax and ₹52.75 crore in penalty, totaling ₹105.50 crore plus interest.
Total quantified demand represents approximately 30.1% of TTM PAT (₹351 crore).
Company is preparing a detailed response to contest the notice before the Joint Commissioner, CGST Roorkee.
👀 What to Watch
Track the subsidiary's response to the tax authorities and subsequent adjudication orders to assess if any liability crystallizes or requires provisioning.
Jubilant Pharmova Gets USFDA Clearance for Commercial Production on Spokane Line 3
Jubilant Pharmova announced that the USFDA has granted approval for commercial batch manufacturing of the first product on Line 3 at its contract manufacturing facility in Spokane, USA. The approval was received on August 21, 2026 (PST) for the new Isolator-based sterile fill-and-finish line operated by subsidiary Jubilant HollisterStier LLC. This operational milestone enables commercial revenue ramp-up in the high-margin sterile injectables CDMO segment.
Confidence: HIGH
What changedUSFDA has approved commercial manufacturing for the initial product on the newly installed Line 3 at the Spokane sterile injectables site.
Why it mattersCommercialization of Line 3 directly supports the company's strategy to expand high-margin CDMO sterile injectables capacity and offset generic pricing pressures.
Approval receipt date: August 21, 2026Facility location: Spokane, WA, U.S.A.Manufacturing line: Line 3 (Isolator-based fill & finish)TTM Revenue context: ₹8,607 Cr
📅 Short termProvides positive sentiment by de-risking regulatory timelines for newly installed sterile fill-finish infrastructure.
📈 Long termSupports structural top-line growth and margin expansion by shifting business mix toward sterile injectables CDMO contracts.
⚠ Risk flags
- Pace of commercial volume ramp-up and client demand uptake
- Ongoing regulatory compliance across USFDA inspections
Key Highlights
USFDA approval received for commercial batch manufacturing of the first product on Line 3.
Line 3 is an advanced Isolator-based fill-and-finish line located in Spokane, WA, USA.
Approval received on August 21, 2026 (12:46 PM PST / August 22, 2026, 01:16 AM IST).
Operated by Jubilant HollisterStier LLC, a step-down wholly owned subsidiary under Jubilant Pharma Limited.
👀 What to Watch
Track the pace of commercial batch ramp-up on Line 3 in upcoming quarterly updates, as well as progress on the Montreal sterile capacity expansion.
